Company overview
Immuto Scientific provides an AI-enabled, high-throughput platform combining mass spectrometry and machine learning for structural surfaceomics analysis, identifying novel disease-specific protein conformations (SPCs) as therapeutic targets, particularly for cancer. The company offers contract research services to support drug discovery against undruggable targets, including patented Plasma-Induced Modification of Biomolecules (PLIMB) technology for assessing drug-target binding. They collaborate with institutions like UW-Madison on colorectal cancer target discovery and advance an internal pipeline of biologics and ADCs for indications such as AML, solid tumors, and NSCLC.
Industry categories: Life Science Reagents, CRO & Clinical Services. These tags help R&D, manufacturing, and procurement teams discover vendors aligned with their pipeline stage and compliance requirements.
Products and technologies associated with Immuto Scientific include Cro, Mass Spectrometry — relevant for pharmaceutical discovery, process development, and GMP manufacturing workflows.
Structured facts
- Website
- https://immutoscientific.com
- Categories
- Life Science Reagents, CRO & Clinical Services
- Markets served
- United States & Americas
- Keywords
- structural surfaceomics, ai mass spectrometry, cancer target discovery, protein conformations, drug discovery cro
Products & technologies
Markets served
Industry categories
Company timeline
- — Profile published on NovaPharmaNews
- — Profile last updated
Related suppliers in category
Frequently asked questions
- What core technology does Immuto Scientific offer for drug discovery?
- Immuto's patented AI-assisted mass spectrometry platform, including PLIMB technology, enables high-throughput characterization of disease surfaceomes to identify novel epitopes and surface protein conformations (SPCs) at ~100 structures per week.
- What services are available for pharmaceutical R&D?
- As a contract research organization, Immuto provides analytical research services for target discovery, structural proteomics, and drug binding optimization, focused on cancer and undruggable targets.
- What is Immuto's therapeutic focus and pipeline?
- Immuto targets cancer with programs like IMTO 4842 (AML, ADC), IMTO 5727 (solid tumors, biologic), and IMTO 3437 (TKI-resistant NSCLC, biologic), leveraging their structural platform for precision therapies.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
